Stock RCE RECCE PHARMACEUTICALS LTD
Add to a list
To use this feature you must be a member
Log inSign up

News Recce Pharmaceuticals Ltd

Equities

RCE

AU000000RCE5

Delayed Australian S.E.
Other stock markets
 09:18:46 2024-04-30 pm EDT 		5-day change 1st Jan Change
0.635 AUD -3.79% Intraday chart for Recce Pharmaceuticals Ltd -2.31% +18.69%
Apr. 17 Recce Pharmaceuticals Ltd. Completes 5,000 RECCE 327 Doses Week Under Good Manufacturing Practice CI
Apr. 16 Recce Pharmaceuticals Advances Production of Anti-Infective Medication MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Recce Pharmaceuticals Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
AQ
Recce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)
AQ
Recce Pharmaceuticals Ltd. Completes 5,000 RECCE 327 Doses Week Under Good Manufacturing Practice
CI
Recce Pharmaceuticals Advances Production of Anti-Infective Medication
MT
Recce Pharmaceuticals Provides Business Update
AQ
Recce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024
AQ
Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives
AQ
Recce Pharmaceuticals Ltd Receives New Patent in Israel for Recce Anti-Infectives
CI
Recce Pharmaceuticals Secures Israeli Patent for Anti-Infective Medication; Shares Rise 5%
MT
Recce Pharmaceuticals Announces RECCE® Trademark Registered in Canada, Strengthening Global IP Portfolio
AQ
Recce Pharmaceuticals Secures Canadian Trademark for Antibiotic Medications
MT
Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
AQ
Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of Recce® 327 for Urinary Tract Infections and Urosepsis
CI
Recce Pharmaceuticals Concludes Cohort Dosing in Synthetic Anti-Infectives Trial
MT
Recce Pharmaceuticals Doses Next Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
AQ
Recce Pharmaceuticals Ltd Doses Next Cohort in Phase I/II Trial of RECCE 327 for Urinary Tract Infections and Urosepsis
CI
Recce Makes Headway On Human Trials of Anti-Infective
MT
Recce Pharmaceuticals to Present at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting
AQ
Recce Pharmaceuticals Receives AUD $11.17 Million Research and Development (R&D) Advance
AQ
Recce Pharmaceuticals Secures AU$11.2 Million R&D Advance; Shares Up 5%
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RCE Stock
  4. News Recce Pharmaceuticals Ltd